A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with
moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or
are intolerant to conventional disease-modifying therapy. A total of approximately 124
subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib
tablets q.d. or matching placebo tablets q.d. The Screening visit will occur within 28 days
before study drug administration. At Day 1 (Baseline), eligible subjects will be randomized
to treatment for a duration of 16 weeks. The study is concluded with a Follow-up period
lasting until 4 weeks after the last dose. Consequently, each subject will stay in the study
for a maximum of 24 weeks (from Screening visit to Follow-up visit).